Visfatin, C-terminal (Human) - EIA Kit, extraction-free


Catalog #
EK-003-80 96 wells $506

  • Protocol:
  • View/Download (PDF) - for reference only
  • Sample Preparation:
  • Suggested Procedure
  • Measured Sample Levels: polaroid
    Measured values represent approximate 'normal' levels in sample, but do not signify the only possible sample levels. Various factors (e.g. sample storage, assay procedure) can affect results.
  • Human Plasma: 25 ng/ml
    Human Serum: 32 ng/ml
  • Sample Extraction:
  • Not required
  • Sensitivity: polaroid
    Data may differ slightly based on lot.
  • 2.3 ng/ml
  • Linear Range: polaroid
    Data may differ slightly based on lot.
  • 2.3 - 40 ng/ml
  • Cross Reactivity:
  • Peptide %
    Visfatin C-terminal (Human) 100
    Visfatin (Human) recombinant (Full Length) 100
    Leptin (Human) 0
    Leptin (Mouse) 0
    Adiponectin (Human) 0
    Adiponectin (Mouse) 0
    Resistin (Human) 0
    Resistin (Mouse) 0
    Insulin (Human) 0
    Resistin (43-65) (Human) 0

  • Intra-assay variation:
  • <10%
  • Inter-assay variation:
  • <15%
  • MSDS:
  • View/Download
Standard Curve:

Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.
Saddi-rosa P, Oliveira C, Crispim F, et al. Cardiovasc Diabetol. 2013;12:119.

Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin.
Eleftheriadis T, Pissas G, Remoundou M, Antoniadi G, Liakopoulos V, Stefanidis I. Ren Fail. 2013;35(10):1399-403.

The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy.
Sonmez FM, Zaman D, Aksoy A, et al. Seizure. 2013;22(10):856-61.

Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies.
Derosa G, Cicero AF, Carbone A, et al. Expert Opin Drug Saf. 2013;12(5):621-9.

Differential regulation of adipokines may influence migratory behavior in the white-throated sparrow (Zonotrichia albicollis).
Stuber EF, Verpeut J, Horvat-gordon M, Ramachandran R, Bartell PA. PLoS ONE. 2013;8(6):e59097.

Clinical role of serum pre-B cell colony-enhancing factor in ventilated patients with sepsis and acute respiratory distress syndrome.
Lee K, Huh JW, Lim CM, Koh Y, Hong SB. Scand J Infect Dis. 2013;45(10):760-5.

One day of mixed meal overfeeding reduces hepatic insulin sensitivity and increases VLDL particle but not VLDL-triglyceride secretion in overweight and obese men.
Smith GI, Magkos F, Reeds DN, Okunade AL, Patterson BW, Mittendorfer B. J Clin Endocrinol Metab. 2013;98(8):3454-62.

Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G, Cicero AF, Franzetti IG, et al. Can J Physiol Pharmacol. 2013;91(9):724-32.

The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity.
Rotkegel S, Chudek J, Spiechowicz-zaton U, Ficek R, Adamczak M, Wiecek A. Kidney Blood Press Res. 2013;37(2-3):124-31.

Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Derosa G, Ragonesi PD, Carbone A, et al. Pharmacol Res. 2013;73:20-6.

Acute and chronic effects of biliopancreatic diversion with duodenal switch surgery on plasma visfatin and apelin levels in patients with severe obesity.
Caron-cantin SM, Martin J, Bastien M, et al. Obes Surg. 2013;23(11):1806-14.

Change in plasma visfatin level after severe traumatic brain injury.
Chen J, Weng JF, Hong WC, Luo LF, Yu W, Luo SD. Peptides. 2012;38(1):8-12.

Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity.
Ismail SA, Mohamed SA. Br J Dermatol. 2012;167(2):436-9.

Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
Derosa G, Cicero AF, D'angelo A, Fogari E, Maffioli P. J Clin Pharm Ther. 2012;37(2):187-95.

Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes.
Mahmood N, Junejo AM, Jamal Q, Awan R. J Pak Med Assoc. 2010;60(11):922-6.

Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide.
Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Cardiovasc Res. 2009;81(2):370-80.

NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.
Skokowa J, Lan D, Thakur BK, et al. Nat Med. 2009;15(2):151-8.

Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
De boer JF, Bahr MJ, Böker KH, Manns MP, Tietge UJ. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G196-201.

Relation of visfatin to cardiovascular risk factors and adipocytokines in patients with impaired fasting glucose.
De luis DA, Sagrado MG, Conde R, Aller R, Izaola O. Nutrition. 2013;29(11-12):1300-3.

The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo.
Li L, Yang G, Shi S, Yang M, Liu H, Boden G. Cytokine. 2009;45(1):12-9.

Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients.
Kato A, Odamaki M, Ishida J, Hishida A. Am J Nephrol. 2009;29(1):31-5.

Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.
Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Clin Endocrinol (Oxf). 2008;69(6):878-84.

Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.
Retnakaran R, Youn BS, Liu Y, et al. Clin Endocrinol (Oxf). 2008;69(6):885-93.

A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).
Younossi ZM, Jarrar M, Nugent C, et al. Obes Surg. 2008;18(11):1430-7.

Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Storka A, Vojtassakova E, Mueller M, et al. Eur J Clin Invest. 2008;38(11):820-6.

Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Panidis D, Farmakiotis D, Rousso D, et al. Eur J Intern Med. 2008;19(6):406-12.

Elevated peripheral visfatin levels in narcoleptic patients.
Dahmen N, Manderscheid N, Helfrich J, et al. PLoS ONE. 2008;3(8):e2980.

The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery.
Botella-carretero JI, Luque-ramírez M, Alvarez-blasco F, Peromingo R, San millán JL, Escobar-morreale HF. Obes Surg. 2008;18(8):1000-6.

Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus.
Brema I, Hatunic M, Finucane F, et al. Diabetes Obes Metab. 2008;10(7):600-2.

Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Palin MF, Labrecque B, Beaudry D, Mayhue M, Bordignon V, Murphy BD. Domest Anim Endocrinol. 2008;35(1):58-73.

Gender specificity of body adiposity and circulating adiponectin, visfatin, insulin, and insulin growth factor-I at term birth: relation to prenatal growth.
Ibáñez L, Sebastiani G, Lopez-bermejo A, Díaz M, Gómez-roig MD, De zegher F. J Clin Endocrinol Metab. 2008;93(7):2774-8.

Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Perez-iglesias R, Vazquez-barquero JL, Amado JA, et al. J Clin Psychopharmacol. 2008;28(3):289-95.

Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients.
De luis DA, Gonzalez sagrado M, Conde R, Aller R, Izaola O, Romero E. Nutrition. 2008;24(6):517-21.

Visceral adiposity without overweight in children born small for gestational age.
Ibáñez L, Lopez-bermejo A, Suárez L, Marcos MV, Díaz M, De zegher F. J Clin Endocrinol Metab. 2008;93(6):2079-83.

Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin.
Yilmaz MI, Saglam M, Qureshi AR, et al. Nephrol Dial Transplant. 2008;23(5):1621-7.

High birth weight and early postnatal weight gain protect obese children and adolescents from truncal adiposity and insulin resistance: metabolically healthy but obese subjects?.
Bouhours-nouet N, Dufresne S, De casson FB, et al. Diabetes Care. 2008;31(5):1031-6.

Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens.
Krzysik-walker SM, Ocón-grove OM, Maddineni SR, Hendricks GL, Ramachandran R. Endocrinology. 2008;149(4):1543-50.

Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis.
Matsui H, Tsutsumi A, Sugihara M, et al. Ann Rheum Dis. 2008;67(4):571-2.

Adipokines and cytokines in non-alcoholic fatty liver disease.
Jarrar MH, Baranova A, Collantes R, et al. Aliment Pharmacol Ther. 2008;27(5):412-21.

Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.
Yilmaz MI, Saglam M, Carrero JJ, et al. Nephrol Dial Transplant. 2008;23(3):959-65.

Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor (PBEF/visfatin) expression and protects them from apoptosis.
Kendal-wright CE, Hubbard D, Bryant-greenwood GD. Placenta. 2008;29(3):255-65.

Adiponectin and visfatin concentrations in children treated with valproic acid.
Rauchenzauner M, Haberlandt E, Scholl-bürgi S, et al. Epilepsia. 2008;49(2):353-7.

Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
Choi KM, Lee JS, Kim EJ, et al. Eur J Endocrinol. 2008;158(2):203-7.

Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men.
Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY. Clin Chim Acta. 2008;387(1-2):31-5.

Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Eur J Pharmacol. 2008;578(2-3):249-52.

Increased plasma visfatin levels in subjects with the metabolic syndrome.
Filippatos TD, Derdemezis CS, Gazi IF, et al. Eur J Clin Invest. 2008;38(1):71-2.

Cord serum visfatin at term birth: maternal smoking unmasks the relation to foetal growth.
López-bermejo A, De zegher F, Díaz-silva M, Vicente MP, Valls C, Ibáñez L. Clin Endocrinol (Oxf). 2008;68(1):77-81.

Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women.
Seo JA, Jang ES, Kim BG, et al. Diabetes Res Clin Pract. 2008;79(1):108-11.

Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.
Mazaki-tovi S, Romero R, Kusanovic JP, et al. J Perinat Med. 2008;36(6):485-96.

Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J
Goldfine AB, Mun EC, Devine E, et al. Clin Endocrinol Metab. 2007;92(12):4678-85.

Molecular characteristics of serum visfatin and differential detection by immunoassays.
Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. J Clin Endocrinol Metab. 2007;92(12):4783-91.

Serum retinol-binding protein 4 concentrations in response to short-term overfeeding in normal-weight, overweight, and obese men.
Shea J, Randell E, Vasdev S, Wang PP, Roebothan B, Sun G. Am J Clin Nutr. 2007;86(5):1310-5.

Circulating visfatin level is correlated with inflammation, but not with insulin resistance.
Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Clin Endocrinol (Oxf). 2007;67(5):796-800.

Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass.
García-fuentes E, García-almeida JM, García-arnés J, et al. Obesity (Silver Spring). 2007;15(10):2391-5.

Effect of exercise training on plasma visfatin and eotaxin levels.
Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Eur J Endocrinol. 2007;157(4):437-42.

The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile.
Wang P, Van greevenbroek MM, Bouwman FG, et al. Pflugers Arch. 2007;454(6):971-6.

The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women.
Chen CC, Li TC, Li CI, et al. Metab Clin Exp. 2007;56(9):1216-20.

Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.
Brentano F, Schorr O, Ospelt C, et al. Arthritis Rheum. 2007;56(9):2829-39.

Serum concentration of visfatin in obese women.
Zahorska-markiewicz B, Olszanecka-glinianowicz M, Janowska J, et al. Metab Clin Exp. 2007;56(8):1131-4.

Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
Hsieh CH, He CT, Lee CH, Wu LY, Hung YJ. Metab Clin Exp. 2007;56(8):1087-92.

Preanalytical influences on the measurement of visfatin by enzyme immuno assay.
Nüsken KD, Nüsken E, Petrasch M, Rauh M, Dötsch J. Clin Chim Acta. 2007;382(1-2):154-6.

Visfatin response to glucose is reduced in women with gestational diabetes mellitus.
Haider DG, Handisurya A, Storka A, et al. Diabetes Care. 2007;30(7):1889-91.

Perinatal circulating visfatin levels in intrauterine growth restriction.
Malamitsi-puchner A, Briana DD, Boutsikou M, Kouskouni E, Hassiakos D, Gourgiotis D. Pediatrics. 2007;119(6):e1314-8.

Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells.
Zhou H, Yang X, Wang N, Zhang Y, Cai G. Mol Cell Endocrinol. 2007;270(1-2):17-22.

Clinical correlates of circulating visfatin levels in a community-based sample.
Ingelsson E, Larson MG, Fox CS, et al. Diabetes Care. 2007;30(5):1278-80.

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance.
Lewandowski KC, Stojanovic N, Press M, et al. Diabetologia. 2007;50(5):1033-7.

Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
Haider DG, Schindler K, Mittermayer F, et al. Clin Pharmacol Ther. 2007;81(4):580-5.

Blood visfatin concentrations in normal full-term pregnancies.
Malamitsi-puchner A, Briana DD, Gourgiotis D, Boutsikou M, Baka S, Hassiakos D. Acta Paediatr. 2007;96(4):526-9.

Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Sandeep S, Velmurugan K, Deepa R, Mohan V. Metab Clin Exp. 2007;56(4):565-70.

Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Metab Clin Exp. 2007;56(4):451-8.

Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Dogru T, Sonmez A, Tasci I, et al. Diabetes Res Clin Pract. 2007; 76(1):24-9,

Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.
Fernández-real JM, Moreno JM, Chico B, López-bermejo A, Ricart W. Diabetes Care. 2007;30(3):616-21.

Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension.
Dogru T, Sonmez A, Tasci I, et al. J Hum Hypertens. 2007;21(2):173-5.

Macrostemonoside A promotes visfatin expression in 3T3-L1 cells.
Zhou H, Yang X, Wang NL, Zhang YO, Cai GP. Biol Pharm Bull. 2007;30(2):279-83.

Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women.
Manco M, Fernandez-real JM, Equitani F, et al. J Clin Endocrinol Metab. 2007;92(2):483-90.

Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization.
Dahl TB, Yndestad A, Skjelland M, et al. Circulation. 2007;115(8):972-80.

Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Sun G, Bishop J, Khalili S, et al. Am J Clin Nutr. 2007;85(2):399-404.

Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Varma V, Yao-borengasser A, Rasouli N, et al. J Clin Endocrinol Metab. 2007;92(2):666-72.

Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
Moschen AR, Kaser A, Enrich B, et al. J Immunol. 2007;178(3):1748-58.

Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise.
Frydelund-larsen L, Akerstrom T, Nielsen S, Keller P, Keller C, Pedersen BK. Am J Physiol Endocrinol Metab. 2007;292(1):E24-31.

Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway.
Yonezawa T, Haga S, Kobayashi Y, Takahashi T, Obara Y. FEBS Lett. 2006;580(28-29):6635-43.

Insulin action in adipose tissue and muscle in hypothyroidism.
Dimitriadis G, Mitrou P, Lambadiari V, et al. J Clin Endocrinol Metab. 2006;91(12):4930-7.

Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin.
Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. J Clin Endocrinol Metab. 2006;91(12):5022-8.

Increase in visfatin after weight loss induced by gastroplastic surgery.
Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G. Obesity (Silver Spring). 2006;14(11):1886-9.

Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.
Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Müller M, Wolzt M. J Clin Endocrinol Metab. 2006;91(11):4702-4.

Free fatty acids normalize a rosiglitazone-induced visfatin release.
Haider DG, Mittermayer F, Schaller G, et al. Am J Physiol Endocrinol Metab. 2006;291(5):E885-90.

Serum visfatin increases with progressive beta-cell deterioration.
López-bermejo A, Chico-julià B, Fernàndez-balsells M, et al. Diabetes. 2006;55(10):2871-5.

The adipokine visfatin is markedly elevated in obese children.
Haider DG, Holzer G, Schaller G, et al. J Pediatr Gastroenterol Nutr. 2006;43(4):548-9.

Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.
Otero M, Lago R, Gomez R, et al. Ann Rheum Dis. 2006;65(9):1198-201.

The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.
Jian WX, Luo TH, Gu YY, et al. Diabet Med. 2006;23(9):967-73.

Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects.
Schindler K, Haider D, Wolzt M, et al. Eur J Clin Invest. 2006;36(9):640-6.

The release of the adipocytokine visfatin is regulated by glucose and insulin.
Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. Diabetologia. 2006;49(8):1909-14.

Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.
Pagano C, Pilon C, Olivieri M, et al. J Clin Endocrinol Metab. 2006;91(8):3165-70.

Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
Nowell MA, Richards PJ, Fielding CA, et al. Arthritis Rheum. 2006;54(7):2084-95.

Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans.
Böttcher Y, Teupser D, Enigk B, et al. J Clin Endocrinol Metab. 2006;91(7):2725-31.

Increased visfatin concentrations in women with gestational diabetes mellitus.
Krzyzanowska K, Krugluger W, Mittermayer F, et al. Clin Sci. 2006;110(5):605-9.

Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin.
Curat CA, Wegner V, Sengenès C, et al. Diabetologia. 2006;49(4):744-7.

Visfatin is an adipokine, but it is not regulated by thiazolidinediones.
Hammarstedt A, Pihlajamäki J, Rotter sopasakis V, et al. J Clin Endocrinol Metab. 2006;91(3):1181-4.

Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
Chen MP, Chung FM, Chang DM, et al. J Clin Endocrinol Metab. 2006;91(1):295-9.

Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.
Berndt J, Klöting N, Kralisch S, et al. Diabetes. 2005;54(10):2911-6.

Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism.
Chan DC, Watts GF, Ng TW, et al. Clin Chem. 2005;51(3):578-85.

Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.
Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. J Clin Endocrinol Metab. 2006;91(4):1578-81.